ARTICLE | Company News
Immune Design boosted by compound pooling deal with Sanofi
October 17, 2014 2:45 AM UTC
Immune Design Corp. (NASDAQ:IMDZ) added $2.22 (11%) to $23.23 on Thursday after it announced a deal with Sanofi (Euronext:SAN; NYSE:SNY) to pool compounds in a discovery and development deal focused on immune therapies for herpes simplex virus (HSV).
The pharma's Sanofi Pasteur unit is contributing HSV529, a vaccine containing replicative-defective HSV-2 in a Phase I trial sponsored by NIH, with data expected in 2016. The biotech is contributing preclinical asset G103, a trivalent vaccine candidate that combines a toll-like receptor 4 ( TLR4) agonist with rationally selected antigens from the biotech's GLAAS platform to boost dendritic cells. ...